Principle Investigator:
Zhonglin Hao, MD, PhD
“SNX-5422-CLN1-006; A Phase 1, Open-label, Dose-escalation Study of SNX 5422 plus Carboplatin and Paclitaxel in Subjects with Selected Solid Tumors” Sponsor: Esanex Inc.
Principle Investigator:
Zhonglin Hao, MD, PhD
“SNX-5422-CLN1-006; A Phase 1, Open-label, Dose-escalation Study of SNX 5422 plus Carboplatin and Paclitaxel in Subjects with Selected Solid Tumors” Sponsor: Esanex Inc.
Principle Investigator: Samir Khleif, MD “D4193C00001; A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)” Sponsor: AstraZeneca...
Principle Investigator: Frank Mott, MD “RTOG1216; Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head...
Principle Investigator: Colleen McDonough, MD “ANHL1131; Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients” Sponsor: Children’s Oncology Group “AEWS1221;...
Principle Investigator: Sharad Ghamande, MD “GOG-0229O; A Randomized Phase II Study with a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with...
Sharad Ghamande, MD, received $158K from VentiRx Pharmaceuticals for “A randomized, double-blind, placebo-controlled phase II study of VTX 2337 in combination with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent...